Cargando…

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

In the last few years, there has been a twist in cancer treatment toward immunotherapy thanks to the impressive results seen in advanced patients from several tumor pathologies. Cutaneous melanoma is a highly mutated and immunogenic tumor that has been a test field for the development of immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Aris, Mariana, Mordoh, José, Barrio, María Marcela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609554/
https://www.ncbi.nlm.nih.gov/pubmed/28970830
http://dx.doi.org/10.3389/fimmu.2017.01024
_version_ 1783265630268424192
author Aris, Mariana
Mordoh, José
Barrio, María Marcela
author_facet Aris, Mariana
Mordoh, José
Barrio, María Marcela
author_sort Aris, Mariana
collection PubMed
description In the last few years, there has been a twist in cancer treatment toward immunotherapy thanks to the impressive results seen in advanced patients from several tumor pathologies. Cutaneous melanoma is a highly mutated and immunogenic tumor that has been a test field for the development of immunotherapy. However, there is still a way on the road to achieving complete and long-lasting responses in most patients. It is desirable that immunotherapeutic strategies induce diverse immune reactivity specific to tumor antigens, including the so-called neoantigens, as well as the blockade of immunosuppressive mechanisms. In this review, we will go through the role of promising monoclonal antibodies in cancer immunotherapy with immunomodulatory function, especially blocking of the inhibitory immune checkpoints CTLA-4 and PD-1, in combination with different immunotherapeutic strategies such as vaccines. We will discuss the rational basis for these combinatorial approaches as well as different schemes currently under study for cutaneous melanoma in the clinical trials arena. In this way, the combination of “push and release” immunomodulatory therapies can contribute to achieving a more robust and durable antitumor immune response in patients.
format Online
Article
Text
id pubmed-5609554
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56095542017-10-02 Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma Aris, Mariana Mordoh, José Barrio, María Marcela Front Immunol Immunology In the last few years, there has been a twist in cancer treatment toward immunotherapy thanks to the impressive results seen in advanced patients from several tumor pathologies. Cutaneous melanoma is a highly mutated and immunogenic tumor that has been a test field for the development of immunotherapy. However, there is still a way on the road to achieving complete and long-lasting responses in most patients. It is desirable that immunotherapeutic strategies induce diverse immune reactivity specific to tumor antigens, including the so-called neoantigens, as well as the blockade of immunosuppressive mechanisms. In this review, we will go through the role of promising monoclonal antibodies in cancer immunotherapy with immunomodulatory function, especially blocking of the inhibitory immune checkpoints CTLA-4 and PD-1, in combination with different immunotherapeutic strategies such as vaccines. We will discuss the rational basis for these combinatorial approaches as well as different schemes currently under study for cutaneous melanoma in the clinical trials arena. In this way, the combination of “push and release” immunomodulatory therapies can contribute to achieving a more robust and durable antitumor immune response in patients. Frontiers Media S.A. 2017-08-25 /pmc/articles/PMC5609554/ /pubmed/28970830 http://dx.doi.org/10.3389/fimmu.2017.01024 Text en Copyright © 2017 Aris, Mordoh and Barrio. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Aris, Mariana
Mordoh, José
Barrio, María Marcela
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title_full Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title_fullStr Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title_full_unstemmed Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title_short Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
title_sort immunomodulatory monoclonal antibodies in combined immunotherapy trials for cutaneous melanoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609554/
https://www.ncbi.nlm.nih.gov/pubmed/28970830
http://dx.doi.org/10.3389/fimmu.2017.01024
work_keys_str_mv AT arismariana immunomodulatorymonoclonalantibodiesincombinedimmunotherapytrialsforcutaneousmelanoma
AT mordohjose immunomodulatorymonoclonalantibodiesincombinedimmunotherapytrialsforcutaneousmelanoma
AT barriomariamarcela immunomodulatorymonoclonalantibodiesincombinedimmunotherapytrialsforcutaneousmelanoma